Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 96Inflammatory Breast Neoplasms 9Carcinoma, Intraductal, Noninfiltrating 8Breast Neoplasms, Male 6Breast Carcinoma In Situ 6Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Neoplasms 3Locally Advanced Breast Cancer 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Patients 2Stress, Psychological 1Postoperative Complications 1Pathologic Complete Response 1Neovascularization, Pathologic 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1Motor Activity 1Margins of Excision 1Inflammation 1Infertility 1High-Risk Cancer 1Head and Neck Neoplasms 1Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer 1Colonic Neoplasms 1Cardiotoxicity 1Carcinoma, Lobular 1Breast Cancer-specific Survival 1Breast Cancer Metastatic 1Breast Cancer Invasive 1

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Neoadjuvant Therapy × Breast × Clear all
NCT07616440 2026-06-04

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase NA Recruiting
20 enrolled
Breast

HER2-positive Breast Cancer

NCT06832904 2025-02-18

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
33 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡